Biomarkers in long-covid-19
AssigneeLondon Health Sciences Centre Research Inc.
InventorDouglas FRASER
Life of this patent
Estimating the term…
Abstract
A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.
Claims15
A method of diagnosing long-COVID-19 in a patient, the method comprising:
- (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.
A method of treating long-COVID-19 in a patient, the method comprising administering to the patient at least one of:
- (i) one or more of the proteins listed in Table 3 having a level in the long-COVID-19 column lower than the level of said one or more proteins in the Healthy and CO VID column, and (ii) an agent that reduces the level of one or more of the proteins listed in Table 3 having a level in the long-COVID column of Table 3 higher than the level of said one or more proteins in the Healthy and CO VID column of Table 3.
15-18. (canceled)
Dependencies are inferred from the claim text.